LON:PXS - Provexis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 0.24 0.00 (0.00 %)
(As of 02/19/2019 01:40 PM ET)
Previous CloseGBX 0.24
Today's RangeGBX 0.24 - GBX 0.24
52-Week RangeGBX 0.36 - GBX 0.70
Volume80,000 shs
Average Volume688,515 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

Receive PXS News and Ratings via Email

Sign-up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Personal Products
SectorConsumer Goods



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

Provexis (LON:PXS) Frequently Asked Questions

What is Provexis' stock symbol?

Provexis trades on the London Stock Exchange (LON) under the ticker symbol "PXS."

Has Provexis been receiving favorable news coverage?

News articles about PXS stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Provexis earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are some of Provexis' key competitors?

Who are Provexis' key executives?

Provexis' management team includes the folowing people:
  • Mr. Charles Dawson Buck, Exec. Chairman (Age 72)
  • Mr. Ian Ford BA (Hons) ACA, Fin. Director, Company Sec. & Exec. Director (Age 53)
  • Dr. Niamh O'Kennedy BSc, MSc, Ph.D., Consultant & Member of Scientific Advisory Board
  • Prof. Asim K. Duttaroy BS MS Ph.D., DSc FICN, Consultant & Member of Scientific Advisory Board

How do I buy shares of Provexis?

Shares of PXS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Provexis' stock price today?

One share of PXS stock can currently be purchased for approximately GBX 0.24.

What is Provexis' official website?

The official website for Provexis is http://www.provexis.org/.

How can I contact Provexis?

Provexis' mailing address is Prospect HSE, 58 Queens Road, READING, RG1 4RP, United Kingdom. The company can be reached via phone at +44-1753-861777.

MarketBeat Community Rating for Provexis (LON PXS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about Provexis and other stocks. Vote "Outperform" if you believe PXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Featured Article: Cost of Debt

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel